Benitec Biopharma
BNTC
12 hedge funds and large institutions have $3.84M invested in Benitec Biopharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
19% less capital inflows, than outflows
Capital inflows: $1.47M | Capital outflows: $1.81M
29% less funds holding
Funds holding: 17 → 12 (-5)
33.77% less ownership
Funds ownership: 83.49% → 49.72% (-34%)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$641K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$588K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$277 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
-$1.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.8K |
| 3 |
Virtu Financial
New York
|
-$13K |
| 4 |
Morgan Stanley
New York
|
-$9.21K |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.11K |
BNTC Hedge Fund Activity: Q3 2023 in Review
12 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2023, worth a combined $3.84M — down 31% from $5.57M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BNTC and 3 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $641K. The largest seller was Suvretta Capital Management, cutting an estimated $1.76M.
- 12 institutional investors held Benitec Biopharma (BNTC) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $3.84M of Benitec Biopharma stock for Q3 2023, down 31% quarter-over-quarter.
- 3 funds opened new Benitec Biopharma positions in Q3 2023 and 8 closed out, a net change of -5 holders.
- The largest Benitec Biopharma buyer in Q3 2023 was Janus Henderson Group, an estimated $641K added.
- The largest Benitec Biopharma seller in Q3 2023 was Suvretta Capital Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q3 2023.